Immunogenicity of meningococcal quadrivalent (serogroup A, C, W135 and Y) tetanus toxoid conjugate vaccine: Systematic review and meta-analysis

Pharmacological Research

Volumn 92, Issue , 2015, Pages 31-39

  Pellegrino, Paolo ^a   Perrone, Valentina ^a   Radice, Sonia ^a   Capuano, Annalisa ^c   Clementi, Emilio ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b SCIENTIFIC INSTITUTE   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

MenACWY TT; Meningococcal meningitis; Meningococcal vaccine

Indexed keywords

MENINGOCOCCUS ACWY TETANUS TOXOID CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG; TETRAVALENT MENINGOCOCCAL SEROGROUPS A, C, W-135 AND Y TETANUS TOXOID CONJUGATE VACCINE;

DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EPIDEMIC MENINGITIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; IMMUNOLOGY; MENINGOCOCCAL INFECTIONS;

HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84923270319     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.10.006     Document Type: Review

References (52)

1. L.H. Harrison Epidemiological profile of meningococcal disease in the United States Clin Infect Dis 50 Suppl. 2 2010 S37 S44
2. L.H. Harrison, C.L. Trotter, and M.E. Ramsay Global epidemiology of meningococcal disease Vaccine 27 Suppl. 2 2009 B51 B63
3. L. Ostergaard, S.A. Silfverdal, J. Berglund, C.E. Flodmark, C. West, and V. Bianco A tetravalent meningococcal serogroups a, c, w-135, and y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with twinrix((r)) in subjects aged 11-17 years: an open, randomised, controlled trial Vaccine 30 2012 774 783
4. P. Pellegrino, C. Carnovale, V. Perrone, D. Salvati, M. Gentili, and T. Brusadelli Epidemiological analysis on two decades of hospitalisations for meningitis in the United States Eur J Clin Microbiol Infect Dis 33 2014 1519 1524
5. J.H. Baumer Guideline review: management of invasive meningococcal disease, sign Arch Dis Child Educ Pract Ed 94 2009 46 49
6. C.L. Trotter, and M.E. Ramsay Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines FEMS Microbiol Rev 31 2007 101 107
7. D.S. Stephens, B. Greenwood, and P. Brandtzaeg Epidemic meningitis, meningococcaemia, and Neisseria meningitidis Lancet 369 2007 2196 2210
8. C.P. Hedari, R.W. Khinkarly, and G.S. Dbaibo Meningococcal serogroups a, c, w-135, and y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease Infect Drug Resist 7 2014 85 99
9. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, and J.P. Ioannidis The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
10. R. Borrow, P. Balmer, and E. Miller Meningococcal surrogates of protection - serum bactericidal antibody activity Vaccine 23 2005 2222 2227
11. G.M. Ruiz-Palacios, L.M. Huang, T.Y. Lin, L. Hernandez, M.L. Guerrero, and A.L. Villalobos Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein d conjugate vaccine coadministered with the tetravalent meningococcal serogroups a, c, w-135 and y tetanus toxoid conjugate vaccine in toddlers: a randomized trial Pediatr Infect Dis J 32 2013 62 71
12. L. Ostergaard, M. Van der Wielen, V. Bianco, and J.M. Miller Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups a, c, w-135, and y tetanus toxoid conjugate vaccine (menacwy-tt) Int J Infect Dis 17 2013 e173 e176
13. S. Lupisan, K. Limkittikul, N. Sosa, P. Chanthavanich, V. Bianco, and Y. Baine Meningococcal polysaccharide a o-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase iii study of healthy adults aged 18 to 25 years Clin Vaccine Immunol 20 2013 1499 1507
14. M. Knuf, O. Romain, K. Kindler, U. Walther, P.M. Tran, and H. Pankow-Culot Immunogenicity and safety of the quadrivalent meningococcal serogroups a, c, w-135 and y tetanus toxoid conjugate vaccine (menacwy-tt) in 2-10-year-old children: results of an open, randomised, controlled study Eur J Pediatr 172 2013 601 612
15. N.P. Klein, Y. Baine, V. Bianco, P.R. Lestrate, A. Naz, and M. Blatter One or two doses of quadrivalent meningococcal serogroups a, c, w-135 and y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children Pediatr Infect Dis 32 2013 760 767
16. G. Dbaibo, N. El-Ayoubi, S. Ghanem, F. Hajar, V. Bianco, and J.M. Miller Immunogenicity and safety of a quadrivalent meningococcal serogroups a, c, w-135 and y tetanus toxoid conjugate vaccine (menacwy-tt) administered to adults aged 56 years and older: results of an open-label, randomized, controlled trial Drugs Aging 30 2013 309 319
17. C. Borja-Tabora, C. Montalban, Z.A. Memish, M. Van der Wielen, V. Bianco, and D. Boutriau Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups a, c, w-135, and y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study BMC Infect Dis 13 2013 116
18. T. Vesikari, A. Forsten, D. Boutriau, V. Bianco, M. Van der Wielen, and J.M. Miller Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups a, c, w-135 and y tetanus toxoid conjugate vaccine in toddlers Hum Vaccine Immunother 8 2012 1892 1903
19. T. Vesikari, A. Forsten, D. Boutriau, V. Bianco, M. Van der Wielen, and J.M. Miller A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups a, c, w-135 and y tetanus toxoid conjugate vaccine in children aged 2-10 years Hum Vaccine Immunother 8 2012 1882 1891
20. M. Knuf, Y. Baine, V. Bianco, D. Boutriau, and J.M. Miller Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (menacwy-tt) in toddlers and young children Hum Vaccine Immunother 8 2012 866 872
21. G. Dbaibo, M. Van der Wielen, M. Reda, F. Medlej, C. Tabet, and D. Boutriau The tetravalent meningococcal serogroups a, c, w-135, and y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine Int J Infect Dis 16 2012 e608 e615
22. G. Dbaibo, N. Macalalad, M.R. Aplasca-De Los Reyes, E. Dimaano, V. Bianco, and Y. Baine The immunogenicity and safety of an investigational meningococcal serogroups a, c, w-135, y tetanus toxoid conjugate vaccine (acwy-tt) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study Hum Vaccine Immunother 8 2012 873 880
23. M.R. Aplasca-De Los Reyes, E. Dimaano, N. Macalalad, G. Dbaibo, V. Bianco, and Y. Baine The investigational meningococcal serogroups a, c, w-135, y tetanus toxoid conjugate vaccine (acwy-tt) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults Hum Vaccine Immunother 8 2012 881 887
24. R. Baxter, Y. Baine, K. Ensor, V. Bianco, L.R. Friedland, and J.M. Miller Immunogenicity and safety of an investigational quadrivalent meningococcal acwy tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age Pediatr Infect Dis J 30 2011 e41 e48
25. M. Knuf, D. Kieninger-Baum, P. Habermehl, P. Muttonen, H. Maurer, and P. Vink A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups a, c, w-135, y tetanus toxoid conjugate (menacwy-tt) vaccine administered in the second year of life and in young children Vaccine 28 2010 744 753
26. L. Ostergaard, E. Lebacq, J. Poolman, G. Maechler, and D. Boutriau Immunogenicity, reactogenicity and persistence of meningococcal a, c, w-135 and y-tetanus toxoid candidate conjugate (menacwy-tt) vaccine formulations in adolescents aged 15-25 years Vaccine 27 2009 161 168
27. T. Vesikari, A. Karvonen, V. Bianco, M. Van der Wielen, and J. Miller Tetravalent meningococcal serogroups a, c, w-135 and y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial Vaccine 29 2011 4274 4284
28. N. Bermal, L.M. Huang, A.P. Dubey, H. Jain, A. Bavdekar, and T.Y. Lin Safety and immunogenicity of a tetravalent meningococcal serogroups a, c, w-135 and y conjugate vaccine in adolescents and adults Hum Vaccine 7 2011 239 247
29. Z.A. Memish, G. Dbaibo, M. Montellano, V.P. Verghese, H. Jain, and A.P. Dubey Immunogenicity of a single dose of tetravalent meningococcal serogroups a, c, w-135, and y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-acwy polysaccharide vaccine with an acceptable safety profile Pediatr Infect Dis J 30 2011 e56 e62
30. S.A. Halperin, Y. Baine, J.B. Domachowske, N. Aggarwal, M. Simon, and J.M. Langley Comparison of the safety and immunogenicity of a novel quadrivalent meningococcal acwy-tetanus toxoid conjugate vaccine and a marketed quadrivalent meningococcal acwy-diphtheria toxoid conjugate vaccine in healthy individuals 10-25 years of age J Pediatric Infect Dis Soc 3 2014 33 42
31. D.M. Granoff, R.K. Gupta, R.B. Belshe, and E.L. Anderson Induction of immunologic refractoriness in adults by meningococcal c polysaccharide vaccination J Infect Dis 178 1998 870 874
32. M.N. Ramasamy, E.A. Clutterbuck, K. Haworth, J. Barel, O. Omar, and A.J. Thompson The immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines: a randomised clinical trial in UK adults Clin Vaccine Immunol 2014
33. I. Goldschneider, E.C. Gotschlich, and M.S. Artenstein Human immunity to the meningococcus I. The role of humoral antibodies J Exp Med 129 1969 1307 1326
34. J.D. Croxtall, and S. Dhillon Meningococcal quadrivalent (serogroups a, c, w135 and y) tetanus toxoid conjugate vaccine (nimenrix) Drugs 72 2012 2407 2430
35. V. Papaevangelou, and N. Spyridis Menacwy-tt vaccine for active immunization against invasive meningococcal disease Expert Rev Vaccines 11 2012 523 537
36. S. Ghanem, S. Hassan, R. Saad, and G.S. Dbaibo Quadrivalent meningococcal serogroups a, c, w, and y tetanus toxoid conjugate vaccine (menacwy-tt): a review Expert Opin Biol Ther 13 2013 1197 1205
37. P. Pellegrino, C. Carnovale, M. Pozzi, S. Antoniazzi, V. Perrone, and D. Salvati On the relationship between human papilloma virus vaccine and autoimmune diseases Autoimmun Rev 13 2014 736 741
38. P. Pellegrino, C. Carnovale, V. Perrone, S. Antoniazzi, M. Pozzi, and E. Clementi No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus Eur J Epidemiol 28 2013 705 707
39. P. Pellegrino, C. Carnovale, V. Perrone, S. Antoniazzi, M. Pozzi, and E. Clementi Can hpv immunisation cause adem? Two case reports and literature review Mult Scler 20 2014 762 763
40. P. Pellegrino, C. Carnovale, V. Perrone, M. Pozzi, S. Antoniazzi, and E. Clementi Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems PLoS ONE 8 2013 pe77766
41. P. Pellegrino, C. Carnovale, V. Perrone, D. Salvati, M. Gentili, and T. Brusadelli On the association between human papillomavirus vaccine and primary ovarian failure Am J Reprod Immunol 71 2014 293 294
42. P. Pellegrino, C. Carnovale, V. Perrone, D. Salvati, M. Gentili, and S. Antoniazzi Human papillomavirus vaccine in patients with systemic lupus erythematosus Epidemiology 25 2014 155 156
43. P. Pellegrino, E. Clementi, A. Capuano, and S. Radice Can vaccines interact with drug metabolism? Pharmacol Res 92 2015 13 17
44. A. Soriano, G. Nesher, and Y. Shoenfeld Predicting post-vaccination autoimmunity: who might be at risk? Pharmacol Res 92 2015 18 22
45. P. Pellegrino, C. Carnovale, V. Perrone, M. Pozzi, S. Antoniazzi, and S. Radice Efficacy of vaccination against influenza in patients with multiple sclerosis: the role of concomitant therapies Vaccine 32 2014 4730 4735
46. K. Haq, and J.E. McElhaney Immunosenescence influenza vaccination and the elderly Curr Opin Immunol 29C 2014 38 42
47. I.H. Haralambieva, H.M. Salk, N.D. Lambert, I.G. Ovsyannikova, R.B. Kennedy, and N.D. Warner Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts Vaccine 32 2014 1946 1953
48. G.A. Poland, R.B. Kennedy, and I.G. Ovsyannikova Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery? PLoS Pathog 7 2011 pe1002344
49. P. Pellegrino, E. Clementi, and S. Radice Re postelimination transmission of measles in the US Am J Epidemiol 180 2014 452
50. P. Pellegrino, F.S. Falvella, V. Perrone, C. Carnovale, T. Brusadelli, and M. Pozzi The first steps towards the era of personalised vaccinology: predicting adverse reactions Pharmacogenomics J 2014
51. C. Ulivieri, and C.T. Baldari Statins from cholesterol-lowering drugs to novel immunomodulators for the treatment of th17-mediated autoimmune diseases Pharmacol Res 88 2014 41 52
52. P.P. Dobesh, and K.M. Olsen Statins role in the prevention and treatment of sepsis Pharmacol Res 88 2014 31 40